Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
|
Jul 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents
|
Jan 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.
|
Oct 2013
|
Am J Hematol
|
aplastic anemia
|
Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia
|
Jun 2014
|
Am J Hematol
|
aplastic anemia
|
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes.
|
Jan 2019
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
|
Oct 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
|
May 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|